Skip to main content
Top
Published in: Journal of Neural Transmission 7/2019

01-07-2019 | Affective Disorder | Neurology and Preclinical Neurological Studies - Review Article

Neuropsychiatric aspects of Parkinson’s disease

Authors: Anna Nagy, Anette Schrag

Published in: Journal of Neural Transmission | Issue 7/2019

Login to get access

Abstract

Throughout the natural history of Parkinson’s Disease (PD), from the pre-diagnostic phase to end stage disease, neuropsychiatric manifestations represent a core feature of the disease. This review summarises current knowledge on the features of depression, anxiety, apathy, fatigue, impulse control disorders (ICDs) and psychosis in PD. These co-morbidities are common and still frequently under-recognised. Their impact on quality of life is considerable, with depression having been shown to be the main determinant of health-related quality of life in PD patients. As well as formal diagnostic criteria, multiple scales have been developed to allow for assessment of these symptoms in both the clinic and research settings. The evidence base for treatment is variable, with increasing evidence for pharmacological and non-pharmacological treatment options for depression, but less robust evidence for the treatment of other neuropsychiatric features. Imaging studies are increasingly providing insight into the neural basis of these symptoms, with the hope that this insight will translate into treatments that can benefit patients.
Literature
go back to reference Abbes M et al (2018) Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatr 89:836–843CrossRef Abbes M et al (2018) Subthalamic stimulation and neuropsychiatric symptoms in Parkinson’s disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatr 89:836–843CrossRef
go back to reference Barone P et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649CrossRefPubMed Barone P et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649CrossRefPubMed
go back to reference Barone P et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580CrossRefPubMed Barone P et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580CrossRefPubMed
go back to reference Broen MPG, Narayen NE, Kuijf ML, Dissanayaka NNW, Leentjens AFG (2016) Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 31:1125–1133CrossRefPubMed Broen MPG, Narayen NE, Kuijf ML, Dissanayaka NNW, Leentjens AFG (2016) Prevalence of anxiety in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 31:1125–1133CrossRefPubMed
go back to reference Brown RG et al (2011) Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatr 82:803–809CrossRef Brown RG et al (2011) Depression and anxiety related subtypes in Parkinson’s disease. J Neurol Neurosurg Psychiatr 82:803–809CrossRef
go back to reference Burn D et al (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 21:1899–1907CrossRefPubMed Burn D et al (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 21:1899–1907CrossRefPubMed
go back to reference Cohen ML, Aita S, Mari Z, Brandt J (2015) The unique and combined effects of apathy and depression on cognition in Parkinson’s disease. J Parkinsons Dis 5:351–359CrossRefPubMed Cohen ML, Aita S, Mari Z, Brandt J (2015) The unique and combined effects of apathy and depression on cognition in Parkinson’s disease. J Parkinsons Dis 5:351–359CrossRefPubMed
go back to reference Corbin L et al (2016) Acupuncture for symptomatic treatment of fatigue in Parkinson’s disease: trial design and implementation. Med Acupunct 28:194–205CrossRefPubMedPubMedCentral Corbin L et al (2016) Acupuncture for symptomatic treatment of fatigue in Parkinson’s disease: trial design and implementation. Med Acupunct 28:194–205CrossRefPubMedPubMedCentral
go back to reference Cummings J et al (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540CrossRefPubMed Cummings J et al (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540CrossRefPubMed
go back to reference Czernecki V et al (2008) Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 23:964–969CrossRefPubMed Czernecki V et al (2008) Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 23:964–969CrossRefPubMed
go back to reference Devos D et al (2014) Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatr 85:668–674CrossRef Devos D et al (2014) Rivastigmine in apathetic but dementia and depression-free patients with Parkinson’s disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatr 85:668–674CrossRef
go back to reference Drijgers RL, Dujardin K, Reijnders JSAM, Defebvre L, Leentjens AFG (2010) Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat Disord 16:656–660CrossRefPubMed Drijgers RL, Dujardin K, Reijnders JSAM, Defebvre L, Leentjens AFG (2010) Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat Disord 16:656–660CrossRefPubMed
go back to reference Fantini ML et al (2018) Sleep and REM sleep behaviour disorder in Parkinson’s disease with impulse control disorder. J Neurol Neurosurg Psychiatr 89:305–310CrossRef Fantini ML et al (2018) Sleep and REM sleep behaviour disorder in Parkinson’s disease with impulse control disorder. J Neurol Neurosurg Psychiatr 89:305–310CrossRef
go back to reference Feldmann A et al (2008) Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord 23:42–46CrossRefPubMed Feldmann A et al (2008) Morphometric changes of gray matter in Parkinson’s disease with depression: a voxel-based morphometry study. Mov Disord 23:42–46CrossRefPubMed
go back to reference Fénelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289:12–17CrossRefPubMed Fénelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289:12–17CrossRefPubMed
go back to reference Forjaz MJ et al (2015) Is the Parkinson anxiety scale comparable across raters? Mov Disord 30:545–551CrossRefPubMed Forjaz MJ et al (2015) Is the Parkinson anxiety scale comparable across raters? Mov Disord 30:545–551CrossRefPubMed
go back to reference Friedman JH, Friedman H (2001) Fatigue in Parkinson’s disease: a nine-year follow-up. Mov Disord 16:1120–1122CrossRefPubMed Friedman JH, Friedman H (2001) Fatigue in Parkinson’s disease: a nine-year follow-up. Mov Disord 16:1120–1122CrossRefPubMed
go back to reference Gallagher DA, Schrag A (2012) Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 46:581–589CrossRefPubMed Gallagher DA, Schrag A (2012) Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 46:581–589CrossRefPubMed
go back to reference Gallagher DA, Parkkinen L, O'Sullivan SS, Spratt A, Shah A, Davey CC, Bremner FD, Revesz T, Williams DR, Lees AJ, Schrag A (2011) Testing an aetiological model of visual hallucinations in Parkinson’s disease. Brain 134(Pt 11):3299–3309CrossRefPubMed Gallagher DA, Parkkinen L, O'Sullivan SS, Spratt A, Shah A, Davey CC, Bremner FD, Revesz T, Williams DR, Lees AJ, Schrag A (2011) Testing an aetiological model of visual hallucinations in Parkinson’s disease. Brain 134(Pt 11):3299–3309CrossRefPubMed
go back to reference Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45:669–671CrossRefPubMed Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45:669–671CrossRefPubMed
go back to reference Gou L et al (2018) Structural brain network alteration and its correlation with structural impairments in patients with depression in de novo and Drug-Naïve Parkinson’s disease. Front Neurol 9:608CrossRefPubMedPubMedCentral Gou L et al (2018) Structural brain network alteration and its correlation with structural impairments in patients with depression in de novo and Drug-Naïve Parkinson’s disease. Front Neurol 9:608CrossRefPubMedPubMedCentral
go back to reference Harding AJ, Broe GA, Halliday GM (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125:391–403CrossRefPubMed Harding AJ, Broe GA, Halliday GM (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125:391–403CrossRefPubMed
go back to reference Jason LA, Evans M, Brown M, Porter N (2010) What is fatigue? pathological and nonpathological fatigue. PM R 2:327–331CrossRefPubMed Jason LA, Evans M, Brown M, Porter N (2010) What is fatigue? pathological and nonpathological fatigue. PM R 2:327–331CrossRefPubMed
go back to reference Lee J-Y et al (2019) Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. J Neurol Neurosurg Psychiatr 90:30–37CrossRef Lee J-Y et al (2019) Behavioural and trait changes in parkinsonian patients with impulse control disorder after switching from dopamine agonist to levodopa therapy: results of REIN-PD trial. J Neurol Neurosurg Psychiatr 90:30–37CrossRef
go back to reference Leentjens AFG et al (2008) Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 23:2004–2014CrossRefPubMed Leentjens AFG et al (2008) Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 23:2004–2014CrossRefPubMed
go back to reference Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P (2014) The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 29(8):1035–1043CrossRefPubMed Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P (2014) The Parkinson Anxiety Scale (PAS): development and validation of a new anxiety scale. Mov Disord 29(8):1035–1043CrossRefPubMed
go back to reference Li Y et al (2014) Clinicogenetic study of GBA mutations in patients with familial Parkinson’s disease. Neurobiol Aging 35(935):e3–e8 Li Y et al (2014) Clinicogenetic study of GBA mutations in patients with familial Parkinson’s disease. Neurobiol Aging 35(935):e3–e8
go back to reference Li D-K et al (2018) Depressive symptoms are associated with color vision but not olfactory function in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 30:122–129CrossRefPubMed Li D-K et al (2018) Depressive symptoms are associated with color vision but not olfactory function in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 30:122–129CrossRefPubMed
go back to reference Lim TT et al (2015) Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord 30:1825–1830CrossRefPubMed Lim TT et al (2015) Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord 30:1825–1830CrossRefPubMed
go back to reference Maillet A et al (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139:2486–2502CrossRefPubMed Maillet A et al (2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139:2486–2502CrossRefPubMed
go back to reference Marsh L, McDonald WM, Cummings J, B.NINDS/NIMH Work Group on Depression and Parkinson’s Disease (2006) Ravina, Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 21:148–158CrossRefPubMed Marsh L, McDonald WM, Cummings J, B.NINDS/NIMH Work Group on Depression and Parkinson’s Disease (2006) Ravina, Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 21:148–158CrossRefPubMed
go back to reference Martinez-Martin P et al (2016) Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson’s disease. Mov Disord 31:270–279CrossRefPubMed Martinez-Martin P et al (2016) Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson’s disease. Mov Disord 31:270–279CrossRefPubMed
go back to reference Martini A, Dal Lago D, Edelstyn NMJ, Grange JA, Tamburin S (2018) Impulse control disorder in Parkinson’s disease: a meta-analysis of cognitive, affective, and motivational correlates. Front Neurol 9:654CrossRefPubMedPubMedCentral Martini A, Dal Lago D, Edelstyn NMJ, Grange JA, Tamburin S (2018) Impulse control disorder in Parkinson’s disease: a meta-analysis of cognitive, affective, and motivational correlates. Front Neurol 9:654CrossRefPubMedPubMedCentral
go back to reference Mayberg HS et al (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28:57–64CrossRefPubMed Mayberg HS et al (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Ann Neurol 28:57–64CrossRefPubMed
go back to reference Meco G, Bernardi S (2007) Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 31:311–313CrossRefPubMed Meco G, Bernardi S (2007) Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 31:311–313CrossRefPubMed
go back to reference Mondolo F et al (2007) Evaluation of anxiety in Parkinson’s disease with some commonly used rating scales. Neurol Sci 28:270–275CrossRefPubMed Mondolo F et al (2007) Evaluation of anxiety in Parkinson’s disease with some commonly used rating scales. Neurol Sci 28:270–275CrossRefPubMed
go back to reference Nassif DV, Pereira JS (2018) Fatigue in Parkinson’s disease: concepts and clinical approach. Psychogeriatrics 18:143–150CrossRefPubMed Nassif DV, Pereira JS (2018) Fatigue in Parkinson’s disease: concepts and clinical approach. Psychogeriatrics 18:143–150CrossRefPubMed
go back to reference Nilsson FM, Kessing LV, Sørensen TM, Andersen PK, Bolwig TG (2002) Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 106:202–211CrossRefPubMed Nilsson FM, Kessing LV, Sørensen TM, Andersen PK, Bolwig TG (2002) Major depressive disorder in Parkinson’s disease: a register-based study. Acta Psychiatr Scand 106:202–211CrossRefPubMed
go back to reference Nomura T et al (2003) Visual hallucinations as REM sleep behavior disorders in patients with Parkinson’s disease. Mov Disord 18:812–817CrossRefPubMed Nomura T et al (2003) Visual hallucinations as REM sleep behavior disorders in patients with Parkinson’s disease. Mov Disord 18:812–817CrossRefPubMed
go back to reference O’Callaghan C, Hornberger M (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 81:694–695CrossRefPubMed O’Callaghan C, Hornberger M (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 81:694–695CrossRefPubMed
go back to reference Papay K et al (2011) Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: validity and variability. Parkinsonism Relat Disord 17:153–155CrossRefPubMed Papay K et al (2011) Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: validity and variability. Parkinsonism Relat Disord 17:153–155CrossRefPubMed
go back to reference Phu AL et al (2014) Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patients. J Clin Neurosci 21:63–66CrossRefPubMed Phu AL et al (2014) Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patients. J Clin Neurosci 21:63–66CrossRefPubMed
go back to reference Picillo M et al (2017) Association between dopaminergic dysfunction and anxiety in de novo Parkinson’s disease. Parkinsonism Relat Disord 37:106–110CrossRefPubMed Picillo M et al (2017) Association between dopaminergic dysfunction and anxiety in de novo Parkinson’s disease. Parkinsonism Relat Disord 37:106–110CrossRefPubMed
go back to reference Poletti M, De Rosa A, Bonuccelli U (2012) Affective symptoms and cognitive functions in Parkinson’s disease. J Neurol Sci 317:97–102CrossRefPubMed Poletti M, De Rosa A, Bonuccelli U (2012) Affective symptoms and cognitive functions in Parkinson’s disease. J Neurol Sci 317:97–102CrossRefPubMed
go back to reference Pontieri FE et al (2015) Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson’s disease. Eur Neuropsychopharmacol 25:69–76CrossRefPubMed Pontieri FE et al (2015) Sociodemographic, neuropsychiatric and cognitive characteristics of pathological gambling and impulse control disorders NOS in Parkinson’s disease. Eur Neuropsychopharmacol 25:69–76CrossRefPubMed
go back to reference Politis M, Loane C (2011) Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. Sci World J 11:1726–1734CrossRef Politis M, Loane C (2011) Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. Sci World J 11:1726–1734CrossRef
go back to reference Pont-Sunyer C et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord 30:229–237CrossRefPubMed Pont-Sunyer C et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord 30:229–237CrossRefPubMed
go back to reference Quelhas R, Costa M (2009) Anxiety, depression, and quality of life in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 21:413–419CrossRefPubMed Quelhas R, Costa M (2009) Anxiety, depression, and quality of life in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 21:413–419CrossRefPubMed
go back to reference Qureshi SU, Amspoker AB, Calleo JS, Kunik ME, Marsh L (2012) Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression. J Geriatr Psychiatry Neurol 25:233–239CrossRefPubMed Qureshi SU, Amspoker AB, Calleo JS, Kunik ME, Marsh L (2012) Anxiety disorders, physical illnesses, and health care utilization in older male veterans with Parkinson disease and comorbid depression. J Geriatr Psychiatry Neurol 25:233–239CrossRefPubMed
go back to reference Ravina B et al (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061–1068CrossRefPubMed Ravina B et al (2007) Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord 22:1061–1068CrossRefPubMed
go back to reference Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189CrossRefPubMed Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189CrossRefPubMed
go back to reference Reijnders JSAM et al (2010) Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord 25:2318–2325CrossRefPubMed Reijnders JSAM et al (2010) Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord 25:2318–2325CrossRefPubMed
go back to reference Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314–1322CrossRefPubMed Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314–1322CrossRefPubMed
go back to reference Richard IH, Justus AW, Kurlan R (2001) Relationship between mood and motor fluctuations in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13:35–41CrossRefPubMed Richard IH, Justus AW, Kurlan R (2001) Relationship between mood and motor fluctuations in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 13:35–41CrossRefPubMed
go back to reference Robert P et al (2009) Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 24:98–104CrossRefPubMed Robert P et al (2009) Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 24:98–104CrossRefPubMed
go back to reference Santangelo G et al (2013) Apathy in Parkinson’s disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol 27:501–513CrossRefPubMedPubMedCentral Santangelo G et al (2013) Apathy in Parkinson’s disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol 27:501–513CrossRefPubMedPubMedCentral
go back to reference Schrag A (2006) Quality of life and depression in Parkinson’s disease. J Neurol Sci 248:151–157CrossRefPubMed Schrag A (2006) Quality of life and depression in Parkinson’s disease. J Neurol Sci 248:151–157CrossRefPubMed
go back to reference Schrag A, Politis M (2016) Serotonergic loss underlying apathy in Parkinson’s disease. Brain 139:2338–2339CrossRefPubMed Schrag A, Politis M (2016) Serotonergic loss underlying apathy in Parkinson’s disease. Brain 139:2338–2339CrossRefPubMed
go back to reference Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2017) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14:57–64CrossRefPubMed Schrag A, Horsfall L, Walters K, Noyce A, Petersen I (2017) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14:57–64CrossRefPubMed
go back to reference Seppi K et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80CrossRefPubMedPubMedCentral Seppi K et al (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80CrossRefPubMedPubMedCentral
go back to reference Sherbaf FG, Same K, Aarabi MH (2018) High angular resolution diffusion imaging correlates of depression in Parkinson’s disease a connectometry study. Acta Neurol Belg 118:573–579CrossRef Sherbaf FG, Same K, Aarabi MH (2018) High angular resolution diffusion imaging correlates of depression in Parkinson’s disease a connectometry study. Acta Neurol Belg 118:573–579CrossRef
go back to reference Siciliano M et al (2018) Fatigue in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 33:1712–1723CrossRefPubMed Siciliano M et al (2018) Fatigue in Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 33:1712–1723CrossRefPubMed
go back to reference Starkstein SE, Leentjens AFG (2008) The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatr 79:1088–1092CrossRef Starkstein SE, Leentjens AFG (2008) The nosological position of apathy in clinical practice. J Neurol Neurosurg Psychiatr 79:1088–1092CrossRef
go back to reference Starkstein SE et al (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:134–139CrossRefPubMed Starkstein SE et al (1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:134–139CrossRefPubMed
go back to reference Starkstein SE, Robinson RG, Leiguarda R, Preziosi TJ (1993) Anxiety and depression in Parkinson’s disease. Behav Neurol 6:151–154CrossRefPubMed Starkstein SE, Robinson RG, Leiguarda R, Preziosi TJ (1993) Anxiety and depression in Parkinson’s disease. Behav Neurol 6:151–154CrossRefPubMed
go back to reference Steeves TDL et al (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132:1376–1385CrossRefPubMed Steeves TDL et al (2009) Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 132:1376–1385CrossRefPubMed
go back to reference Stocchi F, ADAGIO investigators (2014) Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. Eur J Neurol 21:357–360CrossRefPubMed Stocchi F, ADAGIO investigators (2014) Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. Eur J Neurol 21:357–360CrossRefPubMed
go back to reference Thobois S et al (2013) Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 136:1568–1577CrossRefPubMed Thobois S et al (2013) Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 136:1568–1577CrossRefPubMed
go back to reference Timmer MHM, van Beek MHCT, Bloem BR, Esselink RAJ (2017) What a neurologist should know about depression in Parkinson’s disease. Pract Neurol 17:359–368CrossRefPubMed Timmer MHM, van Beek MHCT, Bloem BR, Esselink RAJ (2017) What a neurologist should know about depression in Parkinson’s disease. Pract Neurol 17:359–368CrossRefPubMed
go back to reference Ueda S, Koyama K, Okubo Y (2010) Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 26:111–115CrossRefPubMed Ueda S, Koyama K, Okubo Y (2010) Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 26:111–115CrossRefPubMed
go back to reference Voon V, Fox S, Butler TR, Lang AE (2007) Antidepressants and psychosis in Parkinson disease: a case series. Int J Geriatr Psychiatry 22:601–604CrossRefPubMed Voon V, Fox S, Butler TR, Lang AE (2007) Antidepressants and psychosis in Parkinson disease: a case series. Int J Geriatr Psychiatry 22:601–604CrossRefPubMed
go back to reference Vriend C et al (2014) Depression and impulse control disorders in Parkinson’s disease: two sides of the same coin? Neurosci Biobehav Rev 38:60–71CrossRefPubMed Vriend C et al (2014) Depression and impulse control disorders in Parkinson’s disease: two sides of the same coin? Neurosci Biobehav Rev 38:60–71CrossRefPubMed
go back to reference Vriend C et al (2016) A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. J Neurol Neurosurg Psychiatr 87:493–500CrossRef Vriend C et al (2016) A smaller amygdala is associated with anxiety in Parkinson’s disease: a combined FreeSurfer-VBM study. J Neurol Neurosurg Psychiatr 87:493–500CrossRef
go back to reference Weintraub D, Claassen DO (2017) Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol 133:679–717CrossRefPubMed Weintraub D, Claassen DO (2017) Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol 133:679–717CrossRefPubMed
go back to reference Weintraub D et al (2010a) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68:963–968CrossRefPubMed Weintraub D et al (2010a) Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 68:963–968CrossRefPubMed
go back to reference Weintraub D et al (2010b) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595CrossRefPubMed Weintraub D et al (2010b) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595CrossRefPubMed
go back to reference Weintraub D, Papay K, Xie SX (2015) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 84:1386–1387CrossRefPubMed Weintraub D, Papay K, Xie SX (2015) Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 84:1386–1387CrossRefPubMed
go back to reference Williams DR, Lees AJ (2005) Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 4:605–610CrossRefPubMed Williams DR, Lees AJ (2005) Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 4:605–610CrossRefPubMed
go back to reference Zhu K, van Hilten JJ, Marinus J (2017) Onset and evolution of anxiety in Parkinson’s disease. Eur J Neurol 24:404–411CrossRefPubMed Zhu K, van Hilten JJ, Marinus J (2017) Onset and evolution of anxiety in Parkinson’s disease. Eur J Neurol 24:404–411CrossRefPubMed
go back to reference Zurowski M, O’Brien JD (2015) Developments in impulse control behaviours of Parkinson’s disease. Curr Opin Neurol 28:387–392CrossRefPubMed Zurowski M, O’Brien JD (2015) Developments in impulse control behaviours of Parkinson’s disease. Curr Opin Neurol 28:387–392CrossRefPubMed
Metadata
Title
Neuropsychiatric aspects of Parkinson’s disease
Authors
Anna Nagy
Anette Schrag
Publication date
01-07-2019
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 7/2019
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-019-02019-7

Other articles of this Issue 7/2019

Journal of Neural Transmission 7/2019 Go to the issue

Neurology and Preclinical Neurological Studies - Review Article

Mild cognitive impairment in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

Management of delirium in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

Biomarkers of Parkinson’s disease: 20 years later

Neurology and Preclinical Neurological Studies - Original Article

Disease stage dependency of motor and non-motor fluctuations in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

Sleep–wake and circadian disturbances in Parkinson disease: a short clinical guide